The Council of the Hong Kong Laureate Forum Announced Deferment of Its Inaugural Hong Kong Laureate Forum to November 2022
18.5.2021 11:01:00 EEST | Business Wire | Press release
Given the prevailing situation of the COVID-19 pandemic, the progress of global and local vaccinations, as well as the global position on safe travel, the Board of the Council of the Hong Kong Laureate Forum Limited (the HKLF) has decided after careful consideration that the inaugural Hong Kong Laureate Forum (the Forum), originally scheduled to be held on 15-20 November 2021, would be deferred for one year to November 2022.
Importance of going face-to-face
The Board of the HKLF came to the view that the Forum should ideally be conducted in face-to-face mode given that the main aim of the Forum is to inspire young scientists by providing a platform of direct exchange amongst participating Shaw Laureates and young scientists. However, with the current situation of the pandemic, it is uncertain that safe and unrestricted international travel could be resumed in time for in-person meeting.
Professor Timothy W. TONG, BBS, JP, Chairman of the HKLF, is confident about delivering a successful inaugural Forum next year. He says, “As much as we would have liked to hold this world-class academic exchange event to connect the current and next generations of leaders in scientific pursuit in November this year, it is not a suitable time to do so due to the pandemic. Our Forum aims to inspire young scientists from around the world and provide ample opportunities for exchanges between them and participating Shaw Laureates. We want to ensure that the inaugural Forum fulfils our objective of “Meeting of Inspirational Minds” and I am confident that the inaugural Forum in 2022 will be a great success”.
What happens next
The Secretariat of the HKLF will contact all participating Shaw Laureates and applicants individually as well as their working partners on the deferment. Upon fixing the date of the inaugural Forum next year, all stakeholders will then be notified.
Meanwhile, the Secretariat is planning a series of pre-Forum events targeting different segments of our audience. They would be held over a period of time, starting at end of Q3 this year. These include talk series by renowned scientists and exhibitions on scientific research, etc. Stay tuned to the HKLF website and announcement for details.
Background
The Forum is an annual scientific exchange event organised by the HKLF. It aspires to be a world-class academic exchange event to connect the current and next generations of leaders in scientific pursuit. The Forum also promotes understanding and interests of the young generation in Hong Kong and around the world in various disciplines in science and technology. The HKLF was launched in May 2019 and is fully sponsored by the Lee Shau Kee Foundation. The major partner of the HKLF is The Shaw Prize Foundation which organises the annual international award, The Shaw Prize.
Website: https://www.hklaureateforum.org
Facebook: https://www.facebook.com/HKLaureateForum
Twitter: https://www.twitter.com/HKLaureateForum
Weibo: https://www.weibo.com/hklaureateforum
LinkedIn: https://www.linkedin.com/company/hklaureateforum/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210518005468/en/
Contact information
Forum Programme and Participant Enquiry
Ms Koji Ho
programme@hklaureateforum.org
Tel: (852) 2905 6505
Media Enquiry
Mr Kelvin Chau
media@hklaureateforum.org
Tel: (852) 2905 6506
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 04:45:00 EEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 02:56:00 EEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release
For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom